All AbMole products are for research use only, cannot be used for human consumption.
Sonelokimab (ALX 0761; M 1095) is a trivalent nanobody comprised of monovalent camelid-derived nanobodies specific to human interleukin (IL)-17A, IL-17F, and human serum albumin VHHs. Sonelokimab has the potential for plaque-type psoriasis research.
| CAS Number | 1414386-05-2 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
[1] Sunil Dogra, et al. Expert Opin Biol Ther. Biological treatment for erythrodermic psoriasis
| Related IL Receptor/Related Products |
|---|
| IL-17A modulator-2
IL-17A modulator-2 is a IL-17A modulator. IL-17A modulator-2 inhibits the biological action of IL-17A with a pIC50 of 8.3. IL-17A modulator-2 can be used for the research of diseases associated with modulation of IL-17A activity. |
| IL-15-IN-1
IL-15-IN-1 is a potent and selective Interleukin 15 (IL-15) inhibitor, inhibiting the proliferation of IL-15-dependent cells with an IC50 of 0.8 μM. |
| IL-17 modulator 3
IL-17 modulator 3 is an IL-17 modulator. |
| IL-17 modulator 4
IL-17 modulator 4 is a proagent of IL-17 modulator 1. IL-17 modulator 1 is an orally active, highly efficacious IL-17 modulator. IL-17 modulator 4 is promising for the research of IL-17A mediated diseases, including inflammation, autoimmune diseases, infectious diseases, cancer, and precancerous syndrome. |
| IL-17A modulator-3
IL-17A modulator-3 is a IL-17A modulator. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
